JACC: Cardiovascular Interventions
Focus on TAVR
Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the SAPIEN 3
Victor Mauri, Andreas Reimann, Daniel Stern, Maximilian Scherner, Elmar Kuhn, Volker Rudolph, Stephan Rosenkranz, Kaveh Eghbalzadeh, Kai Friedrichs, Thorsten Wahlers, Stephan Baldus, Navid Madershahian and Tanja K. Rudolph
Table 4
Table 4
Indication, Timing, and Adverse Events of Pacemaker Implantation
| Indication for PPMI | |
| AVB grade III | 29 (87.9) |
| Bradyarrhythmia | 2 (6.1) |
| AVB grade II (Mobitz type II) | 1 (3.0) |
| AVB grade I + LBBB | 1 (3.0) |
| Days to first occurrence of conduction disturbance | 0.5 ± 1.5 |
| First occurrence on same day as TAVR | 29 (87.9) |
| First occurrence 1–3 days post-TAVR | 2 (6.1) |
| First occurrence ≥4 days post-TAVR | 2 (6.1) |
| Days post-TAVR to PPMI | 3.5 ± 4.1 |
| PPMI on same day as TAVR | 8 (24.2) |
| PPMI 1–3 days post-TAVR | 15 (45.5) |
| PPMI ≥4 days post-TAVR | 10 (30.3) |
| PPMI-related adverse events | 3 (9.1) |
| Cardiac tamponade | 1 (3.0) |
| Pneumothorax | 1 (3.0) |
| Bleeding | 1 (3.0) |
Values are n (%) or mean ± SD.
TAVR = transcatheter aortic valve replacement; other abbreviations as in Table 1.
Advertisement